Pivotal Data Put Roche's Kadcyla In Position For Earlier Breast Cancer
KATHERINE supports filings for earlier use of Kadyla in adjuvant setting of breast cancer.
You may also be interested in...
Keeping Track: US FDA Approves Sanofi’s Dengvaxia, But Heron’s HTX-011 And Nabriva’s Contepo Fall Short
The latest drug development news and highlights from our US FDA Performance Tracker.
Biosimilar Litigation Trends: Settlements, Declaratory Judgment Rejections, Congressional Intervention
Of the 27 suits brought so far, four have resulted in patent settlements; restarting patent dance is new trend for ongoing litigation.
Roche's IMpassion130 Is First Positive Phase III Immunotherapy Study In Triple Negative Breast Cancer
Phase III IMpassion130 study showed Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.